Cargando…
MET in gastric cancer – discarding a 10% cutoff rule
AIMS: We aimed to develop a putative predictive biomarker score for future hepatocyte growth factor receptor (MET)‐targeted therapy of gastric cancer (GC). METHODS AND RESULTS: MET expression and MET amplification were analysed by immunohistochemistry (IHC) and chromogenic in‐situ hybridization (CIS...
Autores principales: | Metzger, Marie‐Luise, Behrens, Hans‐Michael, Böger, Christine, Haag, Jochen, Krüger, Sandra, Röcken, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744765/ https://www.ncbi.nlm.nih.gov/pubmed/26033401 http://dx.doi.org/10.1111/his.12745 |
Ejemplares similares
-
Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization
por: Mathiak, Micaela, et al.
Publicado: (2017) -
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
por: Böger, Christine, et al.
Publicado: (2017) -
Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort
por: Röcken, Christoph, et al.
Publicado: (2016) -
Troy is expressed in human stomach mucosa and a novel putative prognostic marker of intestinal type gastric cancer
por: Wilhelm, Franziska, et al.
Publicado: (2016) -
FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort
por: Schrumpf, Thorben, et al.
Publicado: (2022)